deltatrials

Wet age-related macular degeneration Trials in Abilene, United States

Conditions / Wet age-related macular degeneration / Abilene, United States

Research into Wet age-related macular degeneration spans multiple therapeutic approaches and trial phases.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT03790852 Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO TERMINATED PHASE1
NCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 ACTIVE_NOT_RECRUITING PHASE3
NCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK ACTIVE_NOT_RECRUITING
NCT05381948 Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) COMPLETED PHASE2
NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ACTIVE_NOT_RECRUITING
NCT04964089 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) COMPLETED PHASE3
NCT04747197 First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) COMPLETED PHASE1
NCT03748784 ADVM-022 Intravitreal Gene Therapy for Wet AMD COMPLETED PHASE1
NCT04480463 A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) COMPLETED PHASE3
NCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD RECRUITING PHASE3

Related Pages